ストックスクリーナーアプリを入手
15.77
11.13%
1.58
アフターアワーズ：
15.83
0.06
+0.38%
前日終値:
$14.19
開ける：
$14.97
24時間の取引高:
922.74K
Relative Volume:
2.28
時価総額：
$211.40M
収益：
$13.11M
当期純損益:
$-124.02M
株価収益率:
-1.1058
EPS:
-14.261
ネットキャッシュフロー:
$-107.25M
1週間 パフォーマンス:
+17.60%
1か月 パフォーマンス:
+3.07%
6か月 パフォーマンス:
-39.35%
1年 パフォーマンス:
-4.25%
1日の値動き範囲:
$14.93
$16.14
1週間の範囲:
$13.18
$16.14
52週間の値動き範囲:
$13.07
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.77 | 190.22M | 13.11M | -124.02M | -107.25M | -14.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals (TNXP) CEO adds 15,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - GlobeNewswire
Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon - Stock Titan
Tonix Pharmaceuticals Files 8-K Announcing Change in Independent Registered Public Accounting Firm - Minichart
Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings - MarketBeat
Auditor change at Tonix (NASDAQ: TNXP) after going concern warning - Stock Titan
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum (NASDAQ:TNXP) - Seeking Alpha
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ - MSN
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Sahm
Understanding Momentum Shifts in (TNXP) - Stock Traders Daily
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com South Africa
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge - Intellectia AI
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results - MarketBeat
Tonix Pharmaceuticals Holding Corp. Announces Successful Launch of TONMYA™ for Fibromyalgia and Provides 2025 Financial Highlights - Quiver Quantitative
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix presents fibromyalgia drug data at Poland conference By Investing.com - Investing.com South Africa
B2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured Conference - TradingView
TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) Approved by FDA for Fibromyalgia—Tonix Pharmaceuticals Presents Positive Phase 3 Data Showing Rapid Pain Relief and Favorable Benefit-Risk Profile - Minichart
Tonix Pharmaceuticals (TNXP) Highlights New Findings on Tonmya a - GuruFocus
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data - TipRanks
Tonix presents fibromyalgia drug data at Poland conference - Investing.com
Tonix Pharmaceuticals presents Phase 3 post hoc data showing rapid, significant pain relief with TONMYA - TradingView
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia - The Manila Times
TONMYA fibromyalgia data show rapid pain relief, Tonix (NASDAQ: TNXP) - Stock Titan
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday - MarketBeat
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
New fibromyalgia drug Tonmya cuts pain in 14-week trial - Stock Titan
Is Tonix Pharmaceuticals Holding Corp stock a hidden gem2026 Growth vs Value & High Win Rate Trade Tips - baoquankhu1.vn
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating - GlobeNewswire
Is Tonix Pharmaceuticals Holding Corp. stock safe for conservative investors2026 Sector Review & Real-Time Volume Triggers - Naître et grandir
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development - Sahm
TNXP: Tonix Pharmaceuticals Shares Promising Results from Clinical Studies - GuruFocus
TONMYA fibromyalgia tablet under tongue bypasses first-pass liver metabolism - Stock Titan
Tonix Pharmaceuticals Announces Publication of Clinical - GlobeNewswire
Tonix Pharmaceuticals: Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones - TradingView
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):